BACKGROUND: The aim of this study was to investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and its effects on tumor angiogenesis and relapse-free survival (RFS) after curative resection of hepatocellular carcinoma (HCC). METHODS: Expression of CEACAM1 and CD34 was immunohistochemically detected in HCC specimens from 97 patients. Microvessel density (MVD) was determined by counting CD34-positive endothelial cells. Statistical analyses were performed to determine the effects of CEACAM1 on clinicopathologic factors, tumor angiogenesis, and RFS. RESULTS: CEACAM1 expression was detected in 91 HCC specimens; 53 cases showed membranous expression and 38 cases showed cytoplastic expression. CEACAM1 cytoplastic expression was significantly associated with tumor size, number of tumors, vascular invasion, satellite nodules, Edmondson-Steiner grade, TNM stage, and MVD (p < 0.05 for all). Moreover, CEACAM1 cytoplastic expression was significantly associated with poorer RFS. The 3-year RFS of patients with CEACAM1 cytoplastic expression was significantly lower than that of those with CEACAM1 membranous expression (26.3 vs. 52.8%, p = 0.005). Cox analysis revealed that CEACAM1 cytoplastic expression was an independent prognostic factor for 3-year RFS (p = 0.031). CONCLUSION: CEACAM1 expression was common in HCC, and CEACAM1 cytoplastic expression was closely associated with tumor progression, angiogenesis, and poorer RFS, indicating that cytoplastic CEACAM1 might be a predictor of relapsing phenotype and a possible novel target of antiangiogenic therapy for patients with HCC.
BACKGROUND: The aim of this study was to investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and its effects on tumor angiogenesis and relapse-free survival (RFS) after curative resection of hepatocellular carcinoma (HCC). METHODS: Expression of CEACAM1 and CD34 was immunohistochemically detected in HCC specimens from 97 patients. Microvessel density (MVD) was determined by counting CD34-positive endothelial cells. Statistical analyses were performed to determine the effects of CEACAM1 on clinicopathologic factors, tumor angiogenesis, and RFS. RESULTS:CEACAM1 expression was detected in 91 HCC specimens; 53 cases showed membranous expression and 38 cases showed cytoplastic expression. CEACAM1 cytoplastic expression was significantly associated with tumor size, number of tumors, vascular invasion, satellite nodules, Edmondson-Steiner grade, TNM stage, and MVD (p < 0.05 for all). Moreover, CEACAM1 cytoplastic expression was significantly associated with poorer RFS. The 3-year RFS of patients with CEACAM1 cytoplastic expression was significantly lower than that of those with CEACAM1 membranous expression (26.3 vs. 52.8%, p = 0.005). Cox analysis revealed that CEACAM1 cytoplastic expression was an independent prognostic factor for 3-year RFS (p = 0.031). CONCLUSION:CEACAM1 expression was common in HCC, and CEACAM1 cytoplastic expression was closely associated with tumor progression, angiogenesis, and poorer RFS, indicating that cytoplastic CEACAM1 might be a predictor of relapsing phenotype and a possible novel target of antiangiogenic therapy for patients with HCC.
Authors: D Tilki; S Irmak; L Oliveira-Ferrer; J Hauschild; K Miethe; H Atakaya; P Hammerer; M G Friedrich; G Schuch; R Galalae; C G Stief; E Kilic; H Huland; S Ergun Journal: Oncogene Date: 2006-03-27 Impact factor: 9.867
Authors: Darragh P O'Brien; Neomal S Sandanayake; Claire Jenkinson; Aleksandra Gentry-Maharaj; Sophia Apostolidou; Evangelia-Ourania Fourkala; Stephane Camuzeaux; Oleg Blyuss; Richard Gunu; Anne Dawnay; Alexey Zaikin; Ross C Smith; Ian J Jacobs; Usha Menon; Eithne Costello; Stephen P Pereira; John F Timms Journal: Clin Cancer Res Date: 2014-06-17 Impact factor: 12.531